Page 35 - Read Online

chemotherapy as initial treatment for metastatic colorectal Smakal M, Canon JL, Rother M, Williams R, Rong A,
cancer. N Engl J Med 2009;360:1408-17. Wiezorek J, Sidhu R, Patterson SD. Panitumumab-FOLFOX4
76. Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling- treatment and RAS mutations in colorectal cancer.
Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller C, Kahl C, N Engl J Med 2013;369:1023-34.
Seipelt G, Kullmann F, Stauch M, Scheithauer W, Hielscher J, 81. Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA,
Scholz M, Müller S, Link H, Niederle N, Rost A, Höffkes HG, Schutz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506):
Moehler M, Lindig RU, Modest DP, Rossius L, Kirchner T, a new oral multikinase inhibitor of angiogenic, stromal and
Jung A, Stintzing S. FOLFIRI plus cetuximab versus FOLFIRI oncogenic receptor tyrosine kinases with potent preclinical
plus bevacizumab as fi rst-line treatment for patients with antitumor activity. Int J Cancer 2011;129:245-55.
metastatic colorectal cancer (FIRE-3): a randomised, open- 82. Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A,
label, phase 3 trial. Lancet Oncol 2014;10:1065-75. Ychou M, Humblet Y, Bouche O, Mineur L, Barone C,
77. Zhang D, Ye J, Xu T, Xiong B. Treatment related severe Adenis A, Tabernero J, Yoshino T, Lenz HJ, Goldberg RM,
and fatal adverse events with cetuximab in colorectal cancer Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D. Regorafenib
patients: a meta-analysis. J Chemother 2013;25:170-5. monotherapy for previously treated metastatic colorectal
78. Gravalos C, Cassinello J, Garcia-Alfonso P, Jimeno A. cancer (CORRECT): an international, multicentre, randomised,
Integration of panitumumab into the treatment of colorectal placebo-controlled, phase 3 trial. Lancet 2013;381:303-12.
cancer. Crit Rev Oncol Hematol 2010;74:16-26. 83. Chu QS. Afl ibercept (AVE0005): an alternative strategy for
79. Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, inhibiting tumour angiogenesis by vascular endothelial growth
Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, factors. Expert Opin Biol Ther 2009;9:263-71.
Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, 84. Mitchell EP. Targeted therapy for metastatic colorectal cancer:
Smakal M, Canon JL, Rother M, Oliner KS, Wolf M, role of afl ibercept. Clin Colorectal Cancer 2013;12:73-85.
Gansert J. Randomized, phase III trial of panitumumab with 85. Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausova J,
infusional fl uorouracil, leucovorin, and oxaliplatin (FOLFOX4) Macarulla T, Ruff P, van Hazel GA, Moiseyenko V, Ferry D,
versus FOLFOX4 alone as fi rst-line treatment in patients with McKendrick J, Polikoff J, Tellier A, Castan R, Allegra C.
previously untreated metastatic colorectal cancer: the PRIME Addition of afl ibercept to fl uorouracil, leucovorin, and
study. J Clin Oncol 2010;28:4697-705. irinotecan improves survival in a phase III randomized trial
80. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, in patients with metastatic colorectal cancer previously
Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, treated with an oxaliplatin-based regimen. J Clin Oncol
Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, 2012;30:3499-506.

Journal of Cancer Metastasis and Treatment ¦ Volume 1 ¦ Issue 3 ¦ October 15, 2015 ¦ 171